$SGRY

Cantor Fitzgerald reiterated an Overweight rating on Surgery Partners (SGRY) with a $18.00 price target, implying 35% upside. The stock has declined 35% over the past year. Analysts forecast earnings of $0.32 per share for 2026. Q2 2026 results showed a larger-than-expected loss but revenue beat expectations at $848.9 million. Benchmark reiterated a Buy rating with a $24 price target, citing portfolio optimization.

Cantor Fitzgerald reiterated an Overweight rating and $18.00 price target on Surgery Partners (SGRY), citing outpatient volume trends and revenue growth guidance. The stock has fallen 8% in a week. Q2 2026 earnings showed a larger-than-expected loss but revenue beat estimates. The company expects to turn profitable this year, with analysts forecasting $0.32 EPS. The pending sale of two hospitals is part of its portfolio optimization strategy.

TD Cowen reiterated a 'Buy' rating for Surgery Partners (SGRY) with a $19 price target. The stock is seen as 46.8% undervalued with a GF Value of $24.81. Insider buying totaled $143,500 over 3 months. The company operates surgical facilities, focusing on cost-effective outpatient care. Its GF Score is 59, indicating moderate performance.

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Consolidated Financial Statements On September 14, 2026, Surgery Partners, Inc. (the "Company"), through certain of its subsi diaries, entered into two Securities Purchase Agreements (the "Agreements") to sell it's ownership in

Surgery Partners (SGRY) reported Q2 2026 revenue of $848.9M, up from $826.2M a year prior, but with a wider net loss of $15.0M. The company's M&A spending is below its $200M annual target due to disciplined acquisitions. Management expects revenue to reach $4.0B and earnings $72.9M by 2029, requiring 5.9% yearly revenue growth.

DeLuca Teresa purchased 10,000 shares of Surgery Partners, Inc. (SGRY) at $14.35 ($0.14M total) on 2026-08-18.

Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.

Surgery Partners (SGRY) reported Q2 revenue of $848.9M versus $830.7M estimates and adjusted EPS of $0.10 versus $0.06, with adjusted EBITDA of $125.2M slightly above estimates. Management cited higher-acuity procedure growth and payer mix shift toward government reimbursement. Full-year revenue guidance was reconfirmed at $3.4B midpoint.

The article highlights Q2 results for outpatient and specialty care firms. Surgery Partners (SGRY) reported slowest revenue growth and weaker full-year guidance, with the stock down 1.4% to $15.32. LifeStance (LFST) revenue rose to $435.4M (+26.1%) and shares rose 18.3% to $12.27. U.S. Physical Therapy (USPH) revenue $214.1M (+8.5%) and shares $81.96. Encompass Health (EHC) revenue $1.60B (+9.6%) and shares $124.69. agilon health (AGL) revenue $1.49B (+7.2%), shares $87.56.

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.